OncoSil Medical Ltd is an Australian-based medical device company specializing in the development and commercialization of innovative localized radiation therapies. Its primary focus is the OncoSil device, a single-use brachytherapy implant designed for the treatment of patients with unresectable, locally advanced pancreatic cancer and distal cholangiocarcinoma. This device delivers targeted radioactive material directly to cancerous tissues, aiming to provide a novel treatment option in combination with standard chemotherapies. Operating within the healthcare sector and categorized under medical devices, OncoSil Medical Ltd generates most of its revenue from Europe, with additional activity in Australia and New Zealand. The company’s role in the market is to address significant unmet needs in oncology by offering specialized radiotherapy solutions that may improve patient outcomes where conventional surgical or systemic approaches are limited. Through direct sales and distributor partnerships, OncoSil Medical Ltd has established access to multiple international markets and maintains its global headquarters in Sydney, Australia, with European operations based in Germany.